The most commonly reported side effects of<unk>  therapy in clinical trials were nausea, vomiting, dizziness, sleepiness, itchiness, dry mouth, headache, and fatigue. According to the World Health Organization there is little evidence to judge the abuse potential of<unk> . Although early pre-clinical animal trials suggested that<unk>  has a reduced abuse liability compared to other opioid analgesics the US DEA placed<unk>  into Schedule II, the same category as stronger opioids more commonly used recreationally, such as morphine, oxycodone, and fentanyl.<unk>  has been demonstrated to reduce the seizure threshold in patients.<unk>  should be used cautiously in patients with a history of seizures, and in patients who are also taking one or more other drugs which have also been demonstrated to reduce the seizure threshold. Patients at high risk include those using other serotogenic and adrenergic medications, as well as patients with head trauma, metabolic disorders, and those in alcohol and/or drug withdrawals.<unk>  has been demonstrated to potentially produce hypotension (low blood pressure), and should be used with caution in patients with low blood pressure, and patients who are taking one or more other medications which are also known to reduce blood pressure.
Tapentadol
Tramadol
Desmetramadol
Acetylmethadol
Hydrocodone
Etodolac
Ketorolac
Noroxycodone